EX-1.3 4 exhibit1-3.htm EXHIBIT 1.3 Trillium Therapeutics Inc.: Exhibit 1.3 - Filed by newsfilecorp.com

Exhibit 1.3

CORPORATE ACCESS NUMBER: 2010999734

BUSINESS CORPORATIONS ACT

CERTIFICATE

OF

AMENDMENT

STEM CELL THERAPEUTICS CORP.
AMENDED ITS ARTICLES ON 2013/02/06.



Name/Structure Change Alberta Corporation - Registration Statement

Alberta Amendment Date: 2013/02/06

Service Request Number: 19201516
Corporate Access Number: 2010999734
Legal Entity Name: STEM CELL THERAPEUTICS CORP.
French Equivalent Name:  
Legal Entity Status: Active
   
Alberta Corporation Type: Named Alberta Corporation
New Legal Entity Name: STEM CELL THERAPEUTICS CORP.
New French Equivalent  
Name:  
Nuans Number: 81484748
Nuans Date: 2004/10/05
French Nuans Number:  
French Nuans Date:  
   
Share Structure: REFER TO THE ATTACHED SCHEDULE RE: AUTHORIZED
  SHARES FORMING PART OF THESE ARTICLES
Share Transfers NONE
Restrictions:  
Number of Directors:  
Min Number Of Directors: 3
Max Number Of Directors: 10
Business Restricted To: NONE
Business Restricted From: NONE
  REFER TO THE ATTACHED SCHEDULE RE: OTHER
Other Provisions: PROVISIONS FORMING PART OF THESE ARTICLES
BCA Section/Subsection: SECTION 173(1)(F)
   
Professional Endorsement  
Provided:  
Future Dating Required:  
 


Annual Return

File Year Date Filed
2012 2012/08/07
2011 2011/05/31
2010 2010/06/14

Attachment

Attachment Type Microfilm Bar Code Date Recorded
Director Schedule ELECTRONIC 2004/03/31
Other Rules or Provisions ELECTRONIC 2004/03/31
Share Structure ELECTRONIC 2004/03/31
Consolidation, Split, Exchange ELECTRONIC 2013/02/06

Registration Authorized By: JAMES PARSONS
                                                     OFFICER


SCHEDULE OF SHARE STRUCTURE CONSOLIDATION

Pursuant to Section 173(1)(f) of the Business Corporations Act (Alberta) such that the Corporation's issued and outstanding 186,619,359 Common Shares, representing all of the issued and outstanding shares of such class, shall be consolidated on the basis of 1 new share for every 10 old shares held such that the number of issued and outstanding Common Shares after the consolidation will be 18,661,936. No fractional shares will be issued.